HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Epidermal growth factor receptor pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells.

Abstract
The use of platinum complexes for the therapy of breast cancer is an emerging new treatment modality. To gain insight into the mechanisms underlying cisplatin resistance in breast cancer, we used estrogen receptor-positive MCF-7 cells as a model system. We generated cisplatin-resistant MCF-7 cells and determined the functional status of epidermal growth factor receptor (EGFR), MAPK, and AKT signaling pathways by phosphoreceptor tyrosine kinase and phospho-MAPK arrays. The cisplatin-resistant MCF-7 cells are characterized by increased EGFR phosphorylation, high levels of AKT1 kinase activity, and ERK1 phosphorylation. In contrast, the JNK and p38 MAPK modules of the MAPK signaling pathway were inactive. These conditions were associated with inactivation of the p53 pathway and increased BCL-2 expression. We investigated the expression of genes encoding the ligands for the ERBB signaling cascade and found a selective up-regulation of amphiregulin expression, which occurred at later stages of cisplatin resistance development. Amphiregulin is a specific ligand of the EGFR (ERBB1) and a potent mitogen for epithelial cells. After exposure to cisplatin, the resistant MCF-7 cells secreted amphiregulin protein over extended periods of time, and knockdown of amphiregulin expression by specific short interfering RNA resulted in a nearly complete reversion of the resistant phenotype. To demonstrate the generality and importance of our findings, we examined amphiregulin expression and cisplatin resistance in a variety of human breast cancer cell lines and found a highly significant correlation. In contrast, amphiregulin levels did not significantly correlate with cisplatin resistance in a panel of lung cancer cell lines. We have thus identified a novel function of amphiregulin for cisplatin resistance in human breast cancer cells.
AuthorsNiels Eckstein, Kati Servan, Luc Girard, Di Cai, Georg von Jonquieres, Ulrich Jaehde, Matthias U Kassack, Adi F Gazdar, John D Minna, Hans-Dieter Royer
JournalThe Journal of biological chemistry (J Biol Chem) Vol. 283 Issue 2 Pg. 739-50 (Jan 11 2008) ISSN: 0021-9258 [Print] United States
PMID17942395 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • AREG protein, human
  • Amphiregulin
  • Antineoplastic Agents
  • EGF Family of Proteins
  • Glycoproteins
  • Intercellular Signaling Peptides and Proteins
  • Protein Kinases
  • ErbB Receptors
  • Proto-Oncogene Proteins c-akt
  • Bromodeoxyuridine
  • Cisplatin
Topics
  • Amphiregulin
  • Antineoplastic Agents (pharmacology)
  • Breast Neoplasms
  • Bromodeoxyuridine (pharmacology)
  • Cell Division (drug effects)
  • Cell Line, Tumor
  • Cisplatin (pharmacology)
  • Drug Resistance, Neoplasm
  • EGF Family of Proteins
  • Enzyme-Linked Immunosorbent Assay
  • ErbB Receptors (drug effects, physiology)
  • Female
  • Glycoproteins (physiology)
  • Humans
  • Intercellular Signaling Peptides and Proteins (physiology)
  • Neoplasm Invasiveness
  • Phosphorylation
  • Protein Kinases (drug effects, metabolism)
  • Proto-Oncogene Proteins c-akt (metabolism)
  • Signal Transduction (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: